Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about unit size escalation, not just volume growth. The transcript discusses revenue growth, active surgeon base growth, procedure volumes, etc. But does it mention that the size of individual deals, contracts, projects, or engagements is growing? For example, are surgeons now adopting more products per case? Or are they using more implants per procedure? The transcript mentions that iFuse-Bedrock Granite is being used in short constructs, and that some surgeons use a combination of products for two points of fixation, resulting in higher ASP. That could indicate larger per-case revenue. But is that a comparison against the company's own past? The transcript says: "Granite is providing a significant pull-through opportunity for the overall portfolio, as some surgeons are using some combination of our product to at least two points of fixation across the SI joint on either side resulting in a higher procedure average selling price." That suggests that per-procedure revenue is increasing because they are using more products per case. Also, they mention that iFuse-TORQ is being used in trauma and deformity, expanding indications. But is that about unit size? Possibly. However, the question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. That could be interpreted as each new surgeon adoption or each new hospital contract being larger. But the transcript doesn't explicitly say that new surgeons are starting at a higher level of usage or that new contracts are bigger. It talks about active surgeon growth, but that's more about number of surgeons, not size per surgeon. The mention of higher ASP due to multiple products per case is a per-case revenue increase, but is that a comparison against the company's own past? They say "resulting in a higher procedure average selling price." That implies that the average selling price per procedure is higher than before, which could be due to using more products per case. That is an escalation in unit size (per procedure).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.